Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitochondrial Membranes01:45

Mitochondrial Membranes

17.6K
A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
17.6K
ATP Synthase: Mechanism01:48

ATP Synthase: Mechanism

18.3K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
18.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient Preferences in Neuromuscular Diseases: Insights for Future Drug Development.

JIMD reports·2026
Same author

Adjunctive transcranial DC stimulation in the management of refractory drug-resistant focal epilepsy in POLG mitochondrial disease: A case series.

Seizure·2026
Same author

Mavodelpar in patients with primary mitochondrial myopathy: a phase 1 trial.

Scientific reports·2026
Same author

Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Neurological manifestations and genotype-phenotype correlations in <i>NDUFAF6</i>-associated mitochondrial disease.

Brain communications·2026
Same author

Bi-allelic ATG12 variants impair autophagy and cause a neurodevelopmental disorder.

American journal of human genetics·2026
Same journal

AQP4 and MOG Characterize the Autoantibody Landscape of Checkpoint Blockade-Induced Optic Neuritis.

Annals of neurology·2026
Same journal

Five Issues of Artificial Intelligence in Science: Sailing the Ship of Theseus.

Annals of neurology·2026
Same journal

Reply to "Clinical Value of Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysm".

Annals of neurology·2026
Same journal

Clinical Value of Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysm.

Annals of neurology·2026
Same journal

Imaging of Neurovascular Compression in Thoracic Outlet Syndrome.

Annals of neurology·2026
Same journal

Reply to "Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease".

Annals of neurology·2026
See all related articles

Related Experiment Video

Updated: Mar 17, 2026

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

12.3K

Pseudo-obstruction, stroke, and mitochondrial dysfunction: A lethal combination.

Yi Shiau Ng1, Catherine Feeney1, Andrew M Schaefer1

  • 1Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, United Kingdom.

Annals of Neurology
|July 26, 2016
PubMed
Summary
This summary is machine-generated.

Intestinal pseudo-obstruction (IPO) is an under-recognized complication of the common m.3243A>G mitochondrial disease mutation. Early recognition by neurologists is crucial, as stroke is a key predictor of IPO and poor outcomes, especially with surgery.

More Related Videos

Author Spotlight: Decoding Mitochondrial Aging
08:48

Author Spotlight: Decoding Mitochondrial Aging

Published on: June 30, 2023

5.0K
Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.4K

Related Experiment Videos

Last Updated: Mar 17, 2026

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

12.3K
Author Spotlight: Decoding Mitochondrial Aging
08:48

Author Spotlight: Decoding Mitochondrial Aging

Published on: June 30, 2023

5.0K
Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.4K

Area of Science:

  • Mitochondrial Medicine
  • Gastroenterology
  • Neurology

Background:

  • The m.3243A>G mutation in MTTL1 is the most prevalent cause of mitochondrial disease.
  • Intestinal pseudo-obstruction (IPO) is a recognized but under-appreciated complication of mitochondrial disorders.
  • Limited awareness exists regarding the prevalence and clinical impact of IPO in m.3243A>G mutation carriers.

Purpose of the Study:

  • To determine the prevalence and severity of IPO in patients with m.3243A>G mitochondrial disease.
  • To investigate the clinical outcomes associated with IPO in this patient cohort.
  • To identify predictors for the development of IPO in m.3243A>G mutation carriers.

Main Methods:

  • An observational cohort study of 226 patients with genetically confirmed m.3243A>G mutation.
  • Assessment of clinical, molecular, and radiological characteristics of patients presenting with IPO symptoms.
  • Retrospective analysis of patient data from January 2009 to June 2015.

Main Results:

  • Thirty patients (13%) presented with IPO; 13 had prior stroke-like episodes, and 8 developed IPO during a stroke-like episode.
  • Stroke was identified as the strongest predictor for IPO development, alongside cardiomyopathy, low BMI, and high urinary mutation load.
  • Six patients experienced poor clinical outcomes following surgical interventions for IPO.

Conclusions:

  • IPO is an under-recognized and often misdiagnosed clinical entity in m.3243A>G mitochondrial disease.
  • The strong association with stroke and poor outcomes after surgery underscores the need for high clinical suspicion.
  • Timely neurologist involvement and multidisciplinary care coordination are essential for optimal management of IPO in these patients.